New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation.
Department of Medicine, Lenox Hill Hospital, 100 East 77th St, New York, NY 10075, USA. jansell@lenoxhill.net
Jack
J
Ansell
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism; D002316:Cardiotonic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D006801:Humans; D012307:Risk Factors; D013923:Thromboembolism / Q000453:epidemiology / Q000378:metabolism / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors / Q000378:metabolism
D000925:Anticoagulants; D002316:Cardiotonic Agents; D014812:Vitamin K